Type, oral or IM
Results???
Evidence gap
- Major databases show preclinical mechanistic work on ultrashort peptides and peptide transport, but do not show robust, detailed Cartalax clinical trials with clear mechanisms validated in humans.
- As a result, Cartalax’s mechanism must be considered hypothetical and extrapolated from general ultrashort‑peptide biology rather than being clearly established by journal‑published human research.